Location of Repository

Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia

By Cheryl R. Stein, Charles Poole, Powel Kazanjian and Steven R. Meshnick

Abstract

Meta-analysis shows increased risk for DHPS mutations in patients exposed to sulfa prophylaxis for PCP, but clinical relevance of mutations is not known

Topics: Research
Publisher: Centers for Disease Control and Prevention
OAI identifier: oai:pubmedcentral.nih.gov:3323254
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1992). Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother.
    2. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
    3. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients.
    4. (2002). Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr.
    5. Bias in metaanalysis detected by a simple, graphical test.
    6. Confidence intervals for the number needed to treat.
    7. (1990). Continued benefit from highly active antiretroviral therapy: trends in AIDS-related opportunistic illnesses in a public health care system,
    8. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators.
    9. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.
    10. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study.
    11. (2004). Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia.
    12. (2000). Epidemiology of human immunodeficiency virus–associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis.
    13. (1999). Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med.
    14. (1998). Failure of prophylaxis against
    15. (2003). Genotypes of Pneumocystis jiroveci isolates obtained in Harare, Zimbabwe, and London, United Kingdom. Antimicrob Agents Chemother.
    16. (2004). Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr.
    17. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
    18. Low P-values or narrow confidence intervals: which are more durable?
    19. (1998). Modern epidemiology. Philadelphia: Lippincott Williams and Wilkins;
    20. Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia.
    21. Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis.
    22. Mutations in the dihydropteroate synthase gene of Pneumocystis jiroveii isolates from Portuguese patients with Pneumocystis pneumonia.
    23. (1994). Operating characteristics of a rank correlation test for publication bias.
    24. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
    25. (1998). Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
    26. (2003). Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis.
    27. (1998). Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) investigators. J Acquir Immune Defic Syndr Hum Retrovirol.
    28. Pneumocystis dihydropteroate synthase mutations in patients with Pneumocystis pneumonia who are newly diagnosed with HIV infection.
    29. (2003). Pneumocystis jirovecii dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998-2001 prospective study. Med Mycol.
    30. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
    31. (1999). Random-effects meta-analyses are not always conservative.
    32. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.
    33. (2000). Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis.
    34. (1995). The SCID mouse as an experimental model for the evaluation of antiPneumocystis carinii therapy.
    35. (2003). The WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva: World Health Organization;

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.